Physiochemical and functional evaluation of the first-in-class anti-cancer IgE antibody drug, MOv18, through process development and good manufacturing practice production

Antibodies used for cancer therapy are monoclonal IgGs, but tumor-targeting IgE antibodies have shown enhanced effector cell potency against cancer in preclinical models. Research-grade recombinant IgE antibodies have been generated and studied for several decades. The recent Phase 1 clinical trial...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:mAbs
Principais autores: Heather J Bax, Jitesh Chauhan, Alexandra J McCraw, Melanie Grandits, Chara Stavraka, Heike Lentfer, Tim Hillyer, Simon Carroll, Kim Vigor, Chris Selkirk, Mariangela Figini, Jack Cheeseman, Paulina A Urbanowicz, Richard A Gardner, Daniel I R Spencer, Nigel Westwood, Sarah Mellor, James Spicer, Debra H Josephs, Sophia N Karagiannis
Formato: Artigo
Publicado em: Taylor & Francis Group 2025-12-01
Assuntos:
AllergoOncology
Antibody immunotherapy
Basophil activation test
Cancer
Good manufacturing practice
IgE
Acesso em linha:https://www.tandfonline.com/doi/10.1080/19420862.2025.2451295
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Internet

https://www.tandfonline.com/doi/10.1080/19420862.2025.2451295

Registros relacionados